Cases & Deals

  • Home
  • Practices
  • Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZeneca

Share

Cellectis and AstraZeneca enter into research collaboration and agree on equity investment of up to $220 million by AstraZeneca

November 2023

Client(s) Cellectis SA

Jones Day advised Cellectis in connection with the joint research collaboration agreement entered into with AstraZeneca and initial equity investment by AstraZeneca into Cellectis of $80 million. A potential additional equity investment of $140 million is subject to the approval of the extraordinary general meeting of the shareholders of Cellectis to be held on December 22, 2023, clearance from the French Ministry of Economy according to French foreign direct investment regulations, and other customary closing conditions.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.